deltatrials
Completed PHASE4 NCT00036088

Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia

Sponsor: Eli Lilly and Company

Conditions Schizophrenia
Interventions Olanzapine
Updated 6 times since 2017 Last updated: Jul 18, 2006 Started: Aug 31, 2001 Completion: Jul 31, 2002

A PHASE4 clinical study on Schizophrenia, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 6 data snapshots since 2001. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Change History

6 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

Show 1 earlier version
  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE4

    First recorded

Aug 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aparecida de Goiânia, Brazil, Atlanta, United States, Austin, United States, Barcelona, Spain, Buenos Aires, Argentina, Camberwell, United Kingdom, Caracas, Venezuela, Chicago, United States, Cidra, Puerto Rico, Cincinnati, United States and 50 more location s